Effect of oral estradiol valerate on the high sensitivity C-reactive protein in climacteric SD rats

doi:10.3969/j.issn.1006-7795.2013.04.005

Abstract

Abstract:

Objective To investigate the effects of estrogen on the high sensitivity C-reactive protein(hs-CRP), IL-6. Methods Seventy SPF female SD rats, fifteen-month-old, were randomly divided into two groups by digital table method: treatment group and control group. The treatment group was given estradiol valerate orally, once per day, the control group was orally fed with physiological saline intragastric administration, once per day, fourteen weeks. After the treatment, blood samples were taken from the rats to assess the level of hs-CRP, IL-6.Results Fourteen weeks after intragastric administration, in the treatment group, serum hs-CRP level was lower than that in the control group(P<0.05); while the IL-6 level was lower than that in control group(P>0.05). Conclusion Intragastric administration of estradiol valerate might decrease the hs-CRP, so estradiol may play a positive protective role in cardiovascular disease prevention.

Key words: estradiol valerate, climacteric SD rats, intragastric administration, high sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6), cardiovascular disease

CLC Number:

R246.3

YANG Shulin, RUAN Xiangyan, JIANG Hui, WANG Ying. Effect of oral estradiol valerate on the high sensitivity C-reactive protein in climacteric SD rats[J]. Journal of Capital Medical University, 2013, 34(4): 501-505.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.04.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I4/501

References

[1] Early Breast Cancer Trialists' collaborative Group(EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials[J]. Lancet, 2005,365(9472):1687-1717.

[2] Rabaglio M, Aebi S, Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St. Gallen conference[J]. Lancet Oncol, 2007,8:940-949.

[3] Althuis M D, Fergenbaum J H, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature[J]. Cancer Epidemiol Biomarkers Prev, 2004,13(10):1558.

[4] Crudden G, Chitti R E, Craven R J. Hpr6(heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs[J]. J Pharmacol Exp Ther, 2006,316(1):448-455.

[5] 纪术峰,吴爱国,杨华峰.孕激素膜受体1在乳腺癌的表达及生物学意义[J].南方医科大学学报,2012,32(5):635-638.

[6] Causey M W, Huston L J, Harold D M, et al. Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging[J]. J Surg Res, 2011,171(2):615-622.

[7] Neubauer H, Clare S E, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1[J]. Breast Cancer Res, 2008,10(5):R85

[8] Peluso J J, Pappalardo A, Losel R, et al. Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability[J]. Biol Reprod, 2005,73(2):261-270.

[9] Crudden G, Loesel R, Craven R J. Overexpression of the cytochrome p450 activator hpr6(heme-1 domain protein/human progesterone receptor) in tumors[J]. Tumour Biol, 2005,26(3):142-146.

[10] Cahill M A. Progesterone receptor membrane component 1: an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105(1-5):16-36.

[11] Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells[J]. Climacteric, 2009,12(3):230-239.

[12] Neubauer H, Yang Y, Seeger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J]. Menopause, 2011,18(8):845-850.

[13] Stanczyk F Z. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1?[J]. Menopause, 2011,18(8):833-834.

[14] Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J]. Climacteric, 2012,15(5):467-472.

[15] Ruan X, Schneck H, Schultz S, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells[J]. Gynecol Endocrinol, 2012,28(11):863-866.

[16] Ruan X, Seeger H, Mueck A O. The pharmacology of nomegestrol acetate[J]. Maturitas(J of the European Society of Menopause and Andropause), 2012,71(4):345-353.

[17] Ruan X, Seeger H, Mueck A O. The pharmacology of dienogest[J]. Maturitas(J of the European Society of Menopause and Andropause), 2012,71(4):337-344.

[18] Hand R A, Craven R J. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells[J]. J Cell Biochem, 2003,90(3):534-547.

[19] Cahill M A. Progesterone receptor membrane component 1: an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105(1-5):16-36.

[20] Swiatek-De Lange M, Stampfl A, Hauck S M, et al. Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells[J]. Glia, 2007,55(10):1061-1073.

[21] Olsen J V, Blagoev B, Gnad F, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks[J]. Cell, 2006,127(3):635-648.

[22] Liu L, Wang J, Zhao L, et al. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2[J]. Endocrinology, 2009,150(7):3186-3196.

[23] Liu L, Wang J, Zhao L, et al. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2[J]. Endocrinology, 2009,150(7):3186-3196.

[24] Song B L, De Bose-Boyd R A. Ubiquitination of 3-hydroxy-3-methylglutaryl-CoA reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound ubiquitin ligase[J]. J Biol Chem, 2004,279(27):28798-28806.

[25] Suchanek M, Radzikowska A, Thiele C. Photo-leucine and photo-methionine allow identification of protein-protein interactions in living cells[J]. Nat Methods, 2005,2(4):261-267.

[26] Lee J N, Song B, DeBose-Boyd R A, et al. Sterol-regulated degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78[J]. J Biol Chem, 2006,281(51):39308-39315.

[27] Ahmed I S, Rohe H J, Twist K E, et al. Pgrmcl(progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinil sensitivity[J]. J Biol Chem, 2010,285(32):24775-24782.

[28] Zachariades E, Mparmpakas D, Thomas P, et al. Crucial cross-talk of interleukin-1β and progesterone in human choriocarcinoma[J]. Int J Oncol, 2012,40(5):1358-1364.

[29] 夏想厚,谷俊朝.乳腺癌新辅助内分泌治疗的研究进展[J].中华肿瘤防治杂志,2010,17(24):2066-2069.

[30] 吴晖,欧阳取长,曾亮.年轻女性乳腺癌临床特点及其预后分析[J].中华肿瘤防治杂志,2010,17(14):1104-1107.